当前位置:首页 >财报库 > 报告详情

葛兰素史克Glaxosmithkline(GSK)2025年第三季度财报电话会议纪要「LSE」(英文版)(24页).pdf

上传人: 1****1 编号:998592 2025-12-23 24页 199.28KB

下载:

1、Investor Relations Q3 2025 results 1 Confidential Conference call and webcast for investors and analystsConference call and webcast for investors and analysts Wednesday,Wednesday,29 October29 October 2025 at 12:00 2025 at 12:00 GMGMT T Introduction|Introduction|Constantin FestConstantin Fest Slide 1

2、Slide 1 Conference call and webcast for investors and analysts Slide Slide 2 2|Agenda|Agenda Ladies and gentlemen,a very warm welcome to the GSK Q3 2025 results call.I am delighted to be joined today by Emma Walmsley,Luke Miels,Deborah Waterhouse and Julie Brown,with Tony Wood and David Redfern join

3、ing for Q&A.Todays call will last approximately one hour with the presentation taking around 30 minutes and the remaining time for your questions.Please ask only 1-2 questions so that everyone has a chance to participate.Before we start,please turn to slide 3.Slide Slide 3 3|Cautionary statement reg

4、arding forward|Cautionary statement regarding forward-looking statementslooking statements This is the usual safe-harbour statement.We will comment on our performance using constant exchange rates or CER unless otherwise stated.I will now hand over to Emma on slide 4.Investor Relations Q3 2025 resul

5、ts 2 Confidential Q3 2025 strong performance improves furtherQ3 2025 strong performance improves further|Emma Walmsley|Emma Walmsley Slide 4Slide 4 Thank you and welcome to everybody joining us today.Please turn to the next slide.Slide Slide 5 5|2025 strong performance improves further2025 strong pe

6、rformance improves further:QQ3 3 HighlightsHighlights Our third quarter results once again demonstrate GSKs continued strong performance with positive momentum driving an upgrade in our guidance for the year.They also further demonstrate the quality and strength of GSKs portfolio,with sales driven b

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
- GSK Q3 2025业绩强劲,总收入增长8%,核心运营利润增长11%,核心每股收益增长14%。 - 2025年销售和利润预期上调,预计全年 Specialty Medicines增长中高个位数。 - Blenrep获得美国批准,预计将成为GSK未来3-4年的主要增长动力。 - HIV产品组合持续增长,预计2025年增长约10%。 - 疫苗业务预计将在2025年达到疫苗业务预期范围的顶部。 - 2025年自由现金流增加18亿英镑,达到68.9亿英镑。 - GSK将继续投资于研发,预计2025年研发支出将增长10%。 - GSK预计到2026年将实现31%以上的毛利率。
业绩强劲,未来可期?" 哪些项目值得关注?" 未来增长动力何在?"
客服
商务合作
小程序
服务号
折叠